公开(公告)号：US20210228748A1

公开(公告)日：2021-07-29

申请号：US17159968

申请日：2021-01-27

Applicant: HELMHOLTZ-ZENTRUM DRESDEN - ROSSENDORF E.V.

Inventor： Hans-Jürgen PIETZSCH ,  Martin WALTHER ,  Thomas WÜNSCHE

IPC: A61K51/04 ,  C07B59/00 ,  C07F3/14 ,  C07F17/02 ,  C07F3/12 ,  A61K47/68

Abstract: The present invention relates to in vivo stable 197(m)Hg compounds according to formula (E) for use in nuclear medical diagnostics and endoradionuclide therapy (theranostics), particularly the treatment of cancer, a method for the production of the 197(m)Hg compounds comprising the step of radiolabeling of organic precursor compounds with NCA 197(m)Hg by electrophilic substitution; and the use of the 197(m)Hg compounds for nuclear medical diagnostics and endoradionuclide therapy (theranostics), particularly the treatment of cancer.